Sarcoid-like reaction and vitiligo occurring after nivolumab therapy in a patient with metastatic melanoma. 2019

Kensuke Fukuchi, and Miho Hikawa, and Yusuke Sano, and Akira Kasuya, and Masahiro Aoshima, and Kazuki Tatsuno, and Yutaro Nakamura, and Isao Kosugi, and Yoshiki Tokura
Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077594 Nivolumab A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA. BMS-936558,MDX-1106,ONO-4538,Opdivo,BMS 936558,BMS936558,MDX 1106,MDX1106,ONO 4538,ONO4538
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001706 Biopsy Removal and pathologic examination of specimens from the living body. Biopsies
D012507 Sarcoidosis An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands. Besnier-Boeck Disease,Boeck's Sarcoid,Besnier-Boeck-Schaumann Syndrome,Boeck Disease,Boeck's Disease,Schaumann Disease,Schaumann Syndrome,Schaumann's Syndrome,Besnier Boeck Disease,Besnier Boeck Schaumann Syndrome,Boeck Sarcoid,Boecks Disease,Boecks Sarcoid,Disease, Schaumann,Sarcoid, Boeck's,Sarcoidoses,Schaumann's Syndromes,Syndrome, Besnier-Boeck-Schaumann,Syndrome, Schaumann,Syndrome, Schaumann's
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.

Related Publications

Kensuke Fukuchi, and Miho Hikawa, and Yusuke Sano, and Akira Kasuya, and Masahiro Aoshima, and Kazuki Tatsuno, and Yutaro Nakamura, and Isao Kosugi, and Yoshiki Tokura
May 2016, Chest,
Kensuke Fukuchi, and Miho Hikawa, and Yusuke Sano, and Akira Kasuya, and Masahiro Aoshima, and Kazuki Tatsuno, and Yutaro Nakamura, and Isao Kosugi, and Yoshiki Tokura
September 2017, JAMA dermatology,
Kensuke Fukuchi, and Miho Hikawa, and Yusuke Sano, and Akira Kasuya, and Masahiro Aoshima, and Kazuki Tatsuno, and Yutaro Nakamura, and Isao Kosugi, and Yoshiki Tokura
December 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Kensuke Fukuchi, and Miho Hikawa, and Yusuke Sano, and Akira Kasuya, and Masahiro Aoshima, and Kazuki Tatsuno, and Yutaro Nakamura, and Isao Kosugi, and Yoshiki Tokura
June 2021, Melanoma research,
Kensuke Fukuchi, and Miho Hikawa, and Yusuke Sano, and Akira Kasuya, and Masahiro Aoshima, and Kazuki Tatsuno, and Yutaro Nakamura, and Isao Kosugi, and Yoshiki Tokura
September 2022, Dermatologic therapy,
Kensuke Fukuchi, and Miho Hikawa, and Yusuke Sano, and Akira Kasuya, and Masahiro Aoshima, and Kazuki Tatsuno, and Yutaro Nakamura, and Isao Kosugi, and Yoshiki Tokura
October 2020, Melanoma research,
Kensuke Fukuchi, and Miho Hikawa, and Yusuke Sano, and Akira Kasuya, and Masahiro Aoshima, and Kazuki Tatsuno, and Yutaro Nakamura, and Isao Kosugi, and Yoshiki Tokura
July 2018, Clinical and experimental dermatology,
Kensuke Fukuchi, and Miho Hikawa, and Yusuke Sano, and Akira Kasuya, and Masahiro Aoshima, and Kazuki Tatsuno, and Yutaro Nakamura, and Isao Kosugi, and Yoshiki Tokura
December 2014, Cancer immunology research,
Kensuke Fukuchi, and Miho Hikawa, and Yusuke Sano, and Akira Kasuya, and Masahiro Aoshima, and Kazuki Tatsuno, and Yutaro Nakamura, and Isao Kosugi, and Yoshiki Tokura
January 2024, Case reports in oncology,
Kensuke Fukuchi, and Miho Hikawa, and Yusuke Sano, and Akira Kasuya, and Masahiro Aoshima, and Kazuki Tatsuno, and Yutaro Nakamura, and Isao Kosugi, and Yoshiki Tokura
February 2021, La Revue du praticien,
Copied contents to your clipboard!